Scalfaro, Erik http://orcid.org/0000-0002-7252-3981
Streefkerk, Henk Johan
Merz, Michael
Meier, Christoph
Lewis, David
Article History
First Online: 15 May 2017
Compliance with Ethical Standards
:
: The first author was funded as a Novartis associate during the execution of this work. No other sources of funding were used to assist in the preparation of this study.
: David Lewis has no conflicts of interest that are directly relevant to the content of this study. Dr Lewis is a full-time employee of Novartis Pharmaceuticals AG, Basel Switzerland. Dr Lewis holds shares in Novartis and GlaxoSmithKline, and has options on Novartis stock. Statement regarding conflicts of interest: ‘This publication has not been influenced or amended as a result of my employment or my shareholdings or stock options. I affirm that the content of the draft is scientific, evidenced-based, current and is not subject to bias.’ Christoph Meier has no conflicts of interest that are directly relevant to the content of this study. Henk Johan Streefkerk has no conflicts of interest that are directly relevant to the content of this study. Dr Streefkerk is a full-time employee of Novartis Pharmaceuticals AG, Basel Switzerland. Dr Streefkerk has options on Novartis stock. Michael Merz has no conflicts of interest that are directly relevant to the content of this study. Dr Merz is a full-time employee of Novartis Institutes for BioMedical Research, Basel, Switzerland. Erik Scalfaro has no conflicts of interest that are directly relevant to the content of this study. Mr Scalfaro was an associate of Novartis Pharmaceuticals AG, Basel Switzerland.